4.7 Article

8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors

Journal

JOURNAL OF MEDICINAL CHEMISTRY
Volume 59, Issue 4, Pages 1388-1409

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.5b01635

Keywords

-

Funding

  1. Cancer Research UK [CUK] [C309/A11566]
  2. Avon Foundation for Women [02-2013-52]
  3. AbbVie [1097737]
  4. Bayer Pharma AG
  5. Boehringer Ingelheim
  6. Canada Foundation for Innovation
  7. Eshelman Institute for Innovation
  8. Genome Canada
  9. Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD] [115766]
  10. Janssen
  11. Merck Co.
  12. Novartis Pharma AG
  13. Ontario Ministry of Economic Development and Innovation
  14. Pfizer
  15. Sao Paulo Research Foundation-FAPESP
  16. Takeda
  17. Wellcome Trust [092809/Z/10/Z]
  18. NHS
  19. Biotechnology and Biological Sciences Research Council [BB/L004275/1] Funding Source: researchfish
  20. Cancer Research UK [18245, 11566] Funding Source: researchfish
  21. Engineering and Physical Sciences Research Council [EP/L003376/1] Funding Source: researchfish
  22. BBSRC [BB/L004275/1] Funding Source: UKRI
  23. EPSRC [EP/L003376/1] Funding Source: UKRI

Ask authors/readers for more resources

We report the discovery of N-substituted 4-(pyridin-2-yl)thiazole-2-amine derivatives and their subsequent optimization, guided by structure-based design, to give 8-(1H-pyrazol-3-yl)pyrido[3,4-d]pyrimidin-4(3H)-ones, a series of potent JmjC histone N-methyl lysine demethylase (KDM) inhibitors which bind to Fell) in the active site. Substitution from C4 of the pyrazole moiety allows access to the histone peptide substrate binding site; incorporation of a conformationally constrained 4-phenylpiperidine linker gives derivatives such as 54j and 54k which demonstrate equipotent activity versus the KDM4 (JMJD2) and KDM5 (JARID1) subfamily demethylases, selectivity over representative exemplars of the KDM2, KDM3, and KDM6 subfamilies, cellular permeability in the Caco-2 assay, and, for 54k, inhibition of H3K9Me(3) and H3K4Me(3) demethylation in a cell-based assay.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available